Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Clinical Journal of the American Society of Nephrology : CJASN|June 5, 2016
Patient-Reported Outcomes in Glomerular DiseaseDavid T Selewski, Aliza Thompson, Sarrit Kovacs, et al.
Molecular Immunology|November 21, 1998
Point mutations in the beta chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface areaE C Goyarts, Z Vegh, A M Kalergis, et al.
European Journal of Immunology|August 24, 1999
Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturationE J Papadopoulos, C Sassetti, H Saeki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2016
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related SymptomsPaul G Kluetz, Ashley Slagle, Elektra J Papadopoulos, et al.
The Journal of Pain|February 10, 2015
Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTTION Systematic ReviewShannon M Smith, Florence Paillard, Andrew McKeown, et al.
Cancer|September 5, 2002
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomasFunda Meric, Kenneth R Hess, Datla G K Varma, et al.
Digital Biomarkers|June 26, 2018
Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature ReviewBrian Perry, Will Herrington, Jennifer C Goldsack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2017
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site InspectionsJanice Kim, Harpreet Singh, Kassa Ayalew, et al.
Allergy|December 16, 2019
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammationAudrey Le Floc'h, Jeanne Allinne, Kirsten Nagashima, et al.
Pain|August 22, 2013
Discrepancies between registered and published primary outcome specifications in analgesic trials: ACTTION systematic review and recommendationsShannon M Smith, Anthony T Wang, Anthony Pereira, et al.
Pageof 9